Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Nashville, TN

112 studies for Breast Cancer are recruiting at 144 sites within 50 miles of Nashville, Tennessee, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Nashville.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Nashville

Showing the 50 nearest of 112 studies.
  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: One Oncology - Tennessee Oncology ( Site 0098) (Nashville, TN); SCRI Oncology Partners ( Site 7000) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  2. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: The Children's Hospital at TriStar Centennial (Nashville, TN); Vanderbilt Breast Center at One Hundred Oaks (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  3. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry - Joyce Cancer Clinic (Nashville, TN); SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  4. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    NCT06966700

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Nashville General Hospital ( Site 0017) (Nashville, TN); SCRI Oncology Partners ( Site 7005) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  5. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    NCT07085767

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Clinical Trial Site (Nashville, TN); Clinical Trial Site (Mount Juliet, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  6. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    NCT03424005

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Tennessee Oncology PLLC (Nashville, TN); Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  7. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    NCT04893109

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greco-Hainsworth Centers for Research/Tennessee Oncology (Nashville, TN); SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  8. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    NCT05503797

    • Phase 2
    • Ages 8 years and older
    • Sex: All

    Nearest sites: SCRI - TriStar Medical Group Children's Specialists (Nashville, TN); SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  9. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: Vanderbilt Breast Center at One Hundred Oaks (Nashville, TN); Vanderbilt University/Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  10. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    NCT05579366

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute at Tennessee Oncology (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  11. A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    NCT05683418

    • Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Sarah Cannon Cancer Center (Nashville, TN); Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  12. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Vanderbilt Breast Center at One Hundred Oaks (Nashville, TN); Vanderbilt University/Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  13. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    NCT06253871

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Vanderbilt Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  14. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    NCT06324357

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology, Pllc (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  15. SMP-3124LP in Adults With Advanced Solid Tumors

    NCT06526819

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    NCT06778863

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (SCRI) Oncology Partners (Nashville, TN); Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    NCT06784193

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  18. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    NCT06827236

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greco Hainsworth Center for Research Tennessee Oncology (Nashville, TN); SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. A Study of PHST001 in Advanced Solid Tumors

    NCT06840886

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (SCRI) Oncology Partners (Nashville, TN); Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    NCT06841354

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners ( Site 7004) (Nashville, TN); Tennessee Oncology ( Site 0018) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  21. A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

    NCT06926920

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology, PLLC (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  22. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    NCT07060807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners ( Site 7000) (Nashville, TN); Tennessee Oncology ( Site 0068) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  23. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    NCT07062965

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Henry-Joyce Cancer Clinic (Nashville, TN); SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    NCT07174336

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Nashville General Hospital (Nashville, TN); Sarah Cannon Research Institute SCRI (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    NCT07287917

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute Oncology Partners (Nashville, TN); Vanderbilt-Ingram Cancer Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

    NCT07413939

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (Nashville, TN); Tennessee Oncology Elliston Place Plaza (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  27. Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

    NCT00899301

    • Observational
    • Ages 18 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Nashville Breast Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. The PREDICT Registry:

    NCT03448926

    • Observational
    • Ages 30 to 85 years
    • Sex: Female

    Nearest site: Nashville Breast Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Massive Bio SYNERGY-AI site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    NCT03990896

    • Phase 2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Vanderbilt University (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: US Oncology Research LLC (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    NCT04434040

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    NCT04503265

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    NCT04606446

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    NCT04841148

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

    NCT04872166

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    NCT04895709

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    NCT04981119

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

    NCT05187832

    • Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    NCT05216432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    NCT05366881

    • Observational
    • Ages 40 years and older
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: Vanderbilt-Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    NCT05377996

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (SCRI) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    NCT05422794

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt Breast Center at One Hundred Oaks (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

    NCT05455619

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. ETHAN - ET for Male BC

    NCT05501704

    • Phase 2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Vanderbilt Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

    NCT05523947

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

    NCT05573126

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

    NCT05693766

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University/Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.